Elanco Animal Health Incorporated (NYSE:ELAN) Expected to Post Quarterly Sales of $1.22 Billion

Equities analysts expect that Elanco Animal Health Incorporated (NYSE:ELANGet Rating) will post $1.22 billion in sales for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Elanco Animal Health’s earnings. The highest sales estimate is $1.23 billion and the lowest is $1.21 billion. Elanco Animal Health posted sales of $1.24 billion in the same quarter last year, which would indicate a negative year over year growth rate of 1.6%. The company is expected to issue its next quarterly earnings results before the market opens on Monday, January 1st.

On average, analysts expect that Elanco Animal Health will report full-year sales of $4.78 billion for the current financial year, with estimates ranging from $4.77 billion to $4.79 billion. For the next year, analysts expect that the business will post sales of $4.94 billion, with estimates ranging from $4.90 billion to $4.99 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Elanco Animal Health.

Elanco Animal Health (NYSE:ELANGet Rating) last announced its quarterly earnings results on Thursday, February 24th. The company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.04. Elanco Animal Health had a positive return on equity of 6.59% and a negative net margin of 9.91%. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.10 billion. During the same period in the prior year, the company earned $0.12 earnings per share. The company’s revenue for the quarter was down 2.3% compared to the same quarter last year.

Several research analysts have recently weighed in on ELAN shares. Barclays upped their price objective on Elanco Animal Health from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Monday, February 28th. Zacks Investment Research raised Elanco Animal Health from a “sell” rating to a “hold” rating in a research report on Monday, February 28th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Elanco Animal Health presently has an average rating of “Buy” and a consensus price target of $38.43.

In other Elanco Animal Health news, Director R David Hoover acquired 5,000 shares of the business’s stock in a transaction dated Tuesday, March 1st. The stock was bought at an average cost of $28.66 per share, with a total value of $143,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 6.11% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Clearstead Advisors LLC bought a new position in Elanco Animal Health during the 3rd quarter worth $31,000. Herold Advisors Inc. bought a new position in Elanco Animal Health during the 3rd quarter worth $31,000. CKW Financial Group bought a new position in Elanco Animal Health during the 4th quarter worth $30,000. First Horizon Advisors Inc. bought a new position in Elanco Animal Health during the 3rd quarter worth $36,000. Finally, Benjamin Edwards Inc. increased its stake in Elanco Animal Health by 157.1% during the 4th quarter. Benjamin Edwards Inc. now owns 1,427 shares of the company’s stock worth $40,000 after acquiring an additional 872 shares during the period. Institutional investors own 97.90% of the company’s stock.

Shares of Elanco Animal Health stock traded down $0.01 during trading hours on Tuesday, hitting $26.25. The company’s stock had a trading volume of 3,691,664 shares, compared to its average volume of 3,457,464. Elanco Animal Health has a 12 month low of $24.15 and a 12 month high of $37.49. The stock has a 50 day moving average of $26.53 and a 200 day moving average of $28.68. The company has a quick ratio of 1.16, a current ratio of 1.99 and a debt-to-equity ratio of 0.80.

About Elanco Animal Health (Get Rating)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Recommended Stories

Get a free copy of the Zacks research report on Elanco Animal Health (ELAN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.